If the Americans come into the next raise the company will be higher in capitalisation and probably be headed into an index.
i can’t see the USA leading an issue and allowing Aussie institutions a free ride either.
We must assume that the consolidation is all about packaging for US investors … and the kidney drug is the bait.
The roadmap for kidney trials over 2025 is expected to lob in coming weeks and then it may be ‘action stations’.
I also can’t see the Chairman issuing shares under $2 given the positive outlook and the other options available
If the Americans come into the next raise the company will be...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.025(2.11%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.16 | $45.30K | 38.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4346 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 563 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |